Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.63 |
| ▸ | LPL | P06858 | 12/20 | 0.63 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12781960 | 0.97 | LIPG (0.62) | LIPGLPLDGAT1P4HBPDK2 | |
| SCHEMBL12781939 | 0.95 | LIPG (0.59) | LIPGLPLDGAT1P4HBPDK2 | |
| SCHEMBL2618790 | 0.95 | LIPG (0.59) | LIPGLPLDGAT1P4HBPDK2 | |
| SCHEMBL12781966 | 0.94 | LIPG (0.55) | LIPGLPLDGAT1P4HBPDK2 | |
| SCHEMBL24257896 | 0.94 | LIPG (0.57) | LIPGLPLDGAT1P4HBPDK2 | |
| SCHEMBL17143472 | 0.94 | LIPG (0.57) | LIPGLPLDGAT1P4HBPDK2 | |
| SCHEMBL17143469 | 0.94 | LIPG (0.57) | LIPGLPLDGAT1P4HBPDK2 | |
| SCHEMBL12781953 | 0.92 | LIPG (0.52) | LIPGLPLDGAT1P4HBPDK2 | |
| SCHEMBL26050385 | 0.90 | LIPG (0.54) | LIPGLPLDGAT1P4HBPDK2 | |
| SCHEMBL13414970 | 0.90 | LIPG (0.67) | LIPGLPLDGAT1P4HBPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318948-B2 | Fluorene derivatives and organic electronic device using the same | LG CHEM, LTD. (KR) | 2012-11-27 | — | — | US | disclosed |
| US-8318948-B2 | Fluorene derivatives and organic electronic device using the same | LG CHEM, LTD. (KR) | 2012-11-27 | — | — | US | disclosed |
| US-20100071769-A1 | FLUORENE DERIVATIVES AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEM, LTD. (KR) | 2010-03-25 | — | — | US | disclosed |
| US-20100071769-A1 | FLUORENE DERIVATIVES AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEM, LTD. (KR) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100071769-A1 | FLUORENE DERIVATIVES AND ORGANIC ELECTRONIC DEVICE USING THE SAME | VDAC2, VDAC1, FTO | LIPG 1909/4885LPL 2451/4885DGAT1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.